In this Jan. 26, 2009 file photo, Jeffrey Kindler, left, chairman and CEO of Pfizer, and Bernard Poussot, president, chairman and CEO of Wyeth, speak at a news conference in New York. With Pfizer Inc. about to acquire rival drugmaker Wyeth and its expertise in making pricey and complex biologic drugs, Kindler strongly supports allowing generic versions of them. AP Photo logo AP Photo 8 months ago

In this Jan. 26, 2009 file photo, Jeffrey Kindler, left, chairman and CEO of Pfizer, and Bernard Poussot, president, chairman and CEO of Wyeth, speak at a news conference in New York. With Pfizer Inc. about to acquire rival drugmaker Wyeth and its expertise in making pricey and complex biologic drugs, Kindler strongly supports allowing generic versions of them.